Department of Neurology, Mayo Clinic, Rochester, MN.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Ann Neurol. 2019 Jan;85(1):155-160. doi: 10.1002/ana.25388. Epub 2019 Jan 7.
Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155-160.
尽管人们非常关注使用生物标志物来预测阿尔茨海默病，但在个体层面上可用的信息却很少。我们使用基于人群的梅奥诊所老龄化研究，根据生物标志物组来估计认知障碍的绝对风险。风险随年龄和任何生物标志物异常而增加。例如，一名 75 岁的患者，如果存在淀粉样蛋白和皮质变薄生物标志物异常，那么到 80 岁时认知障碍的几率约为 20%，而如果生物标志物正常，则几率<10%。只有一个异常生物标志物的患者具有类似的中等风险。ANN NEUROL 2019;85:155-160.
